KAYS' Fifth Dimension Therapeutics Plans to Open 'The Sacred Mushroom™' Psilocybin Centers in Oregon, Marking Entry into the Global Psychedelics Market, which is Forecast to Exceed $8 Billion by 2029.
FT. LAUDERDALE, FL / ACCESSWIRE / May 24, 2023 / Kaya Holdings, Inc., ('KAYS' or the 'Company') (OTCQB:KAYS), congratulates Bryan Arnold, a dedicated 9-year Kaya employee and Vice President with KAYS subsidiary Fifth Dimension Therapeutics, Inc. ('FDT'), for being among the first graduates of the Changa Institute and among the first ten (10) state Licensed Psilocybin Facilitators in the United States. The Company is proud of Bryan and look forward to his contribution as we seek to develop and launch 'The Sacred Mushroom™' Psilocybin Centers in accordance with Oregon State law.KAYS' Fifth Dimension Subsidiary Vice President Bryan Arnold is one of the first people to be licensed to facilitate psilocybin experiences in the United States outside of clinical trials in over 50 years.
As reported by Bloomberg in July of 2022, 'the rise in stress levels and the growing rate of chronic diseases throughout the world is predicted to propel the global psychedelic medicines market expansion… the value of the Global Psychedelic Therapeutic Market is expected to grow from US$ 3.61 billion in 2021 to US$8.31 billion by 2028, with a CAGR of 13.2%.'
In January 2023 KAYS announced the launch of its FDT subsidiary to provide psychedelic 'mind care' treatments to veterans suffering from PTSD, addicts seeking to break addiction, individuals with eating disorders, and people with treatment resistant depression and other mental health disorders. We are pleased to report this milestone and will update shareholders as we move forward with our plans to open our first Psilocybin Service Center to service the growing Psychedelics Market.
'An uncomfortable fact is that approximately every 40 seconds someone around the world commits suicide,' stated W. David Jones, KAYS Senior Advisor for Business Development and Financial Operations. 'Picture a football stadium filled with 65,000 fans. That's how many people die from suicide every month, and this doesn't even consider the toll on the millions of family members and friends who are left behind, or the more than 100 million people struggling through their lives because of ineffectual mental health treatments' continued Jones. 'We are moving to establish a unique facility dedicated to helping people leverage the power of psychedelics for richer, fuller, and more joyful living, pursuant to Oregon Health Authority requirements and statutes.'
'My experiences at the Changa Institute transformed my understanding of psychedelics', says Bryan Arnold, Vice President of the Company's Psychedelic unit. 'I have gained a tremendous respect for the power of psychedelics and am excited by the potential it has to help people with certain mental health conditions. Being part of the KAYS team introducing psychedelics to the people of Oregon is both a responsibility and an honor, and The Sacred Mushroom™ will reflect our deep respect for psychedelics and the potential they hold to help or heal,' Arnold continues.
Changa Institute Graduates First Licensed US Psychedelic Facilitators:
Updated Information about Kaya Holdings, Inc. http://icont.ac/4QBdX
Kaya Holdings, Inc. (OTCQB:KAYS) is a Mind Care Company with longstanding operations as a touch-the-plant, vertically integrated legal cannabis business. The Company is evolving into a full mind care enterprise with the planned introduction of psilocybin and ketamine treatments, as permitted by State Law, as we seek to expand our medical cannabis business overseas. KAYS is a fully reporting, US-based publicly traded company, listed for trading on the OTCQB Tier of the over-the-counter market under the symbol KAYS.
Shareholder Hotline: For more information, please call 954-480-1270 or email firstname.lastname@example.org to speak with our new Corporate Communications Manager regarding your investment in KAYS.
KAYS SHAREHOLDERS AND OTHER INTERESTED PARTIES - PLEASE UPDATE YOUR CONTACT INFORMATION
We routinely receive calls and emails from shareholders asking us questions about KAYS, so we are asking all KAYS shareholders to email us and confirm their contact info. Please email email@example.com with 'KAYS shareholder update' in the subject line and include your name, address, phone number and number of shares you own so that we may make sure you receive all updates and can respond to any shareholder inquiries.
Summary of Operations
KAYS corporate structure includes the following four majority-owned subsidiaries, each responding to various demands and opportunities in the cannabis or psychedelic industry:
Fifth Dimension Therapeutics, Inc. , serves as the Company's operating branch to the psychedelic treatment sector, including operation of mushroom cultivation facilities and in-facility treatment centers.
Marijuana Holdings Americas, Inc. owns the Kaya Shack™ brand of licensed medical and recreational marijuana stores (www.kayashack.com) and the Kaya Farms™ brand of cannabis production and processing operations that operate in the United States.
Kaya Brands International, Inc., serves as the vehicle for the Company's non-U.S. operations including cultivation activities in Greece and Israel.
Kaya Brands USA, Inc. owns a wide range of proprietary brands of cannabis extracts, oils, pre-rolls, topicals, edibles and beverages, cannaceuticals and related accessories.
KAYS is planning execution of its stated business objectives in accordance with current understanding of state and local laws and federal enforcement policies and priorities as it relates to cannabis and psychedelics. Potential investors and shareholders are cautioned that KAYS and subsidiaries including FTD will obtain advice of counsel prior to actualizing any portion of their business plan (including but not limited to license applications for the cultivation, distribution or sale of marijuana and psychedelic products, engaging in said activities or acquiring existing production/sales operations). Advice of counsel with regard to specific activities of KAYS, federal, state or local legal action or changes in federal government policy and/or state and local laws may adversely affect business operations and shareholder value. Success of our business plan including the launch of 'The Sacred Mushroom™' Psilocybin Facilitation Centers depends on many factors including receipt of requisite funding to build out and staff the Centers.
This press release includes statements that may constitute 'forward-looking' statements, usually containing the words 'believe,' 'estimate,' 'project,' 'expect' or similar statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
SOURCE: Kaya Holdings, Inc.
View source version on accesswire.com: https://www.accesswire.com/756919/Kaya-Holdings-Incs-VP-Bryan-Arnold-Among-First-Ten-10-State-Licensed-Psilocybin-Facilitators-in-USA